The primary development model for producing human recombinant proteins in tobacco is based on green tissue (leaf) biomass processing.
Since the 1980s, the use of human proteins to treat and cure diseases has comprised an increasingly significant sector of the pharmaceutical industry. In 2003, an estimated $39 billion of protein therapeutics were sold in the US. In the next ten years, domestic sales of protein pharmaceuticals are estimated to grow to $359 billion.1
While traditional drugs are chemically synthesized, living organisms produce therapeutic proteins. The current generation of microbial and mammalian cell bioreactor-based systems will not be able to handle future …
No comments:
Post a Comment